Leadership Team

Tom Rossi , , , President and Chief Executive Officer

Tom Rossi serves as President and Chief Executive Officer of Acerus Pharmaceuticals Corporation. Mr. Rossi has over 25 years of experience in the pharmaceutical industry in Canada and abroad. Previously, Mr. Rossi held a variety of leadership positions within Novartis. Most recently, Mr. Rossi was CEO and Country President for Novartis Pharmaceuticals Canada and served as a member of the Rx&D Board of Directors. Prior to returning to Canada, Mr. Rossi was CEO and Country President for Novartis Pharmaceuticals Belgium and was a member of the Novartis Pharma European Executive Committee. Mr. Rossi joined Novartis from Merck Canada and began his healthcare career with Johnson & Johnson. Mr. Rossi holds a Bachelor of Science degree in Microbiology and Immunology from McGill University. In addition, Mr. Rossi received a Master of Business Administration from the John Molson School of Business (Concordia University) focused on Pharmaceutical Marketing.

Tricia Symmes , , , Chief Operating Officer

Ms. Symmes serves as Chief Operating Officer of Acerus Pharmaceuticals Corporation, leading the development and execution of Acerus Pharma’s commercialization strategy, business development, and corporate communications. Ms. Symmes brings more than 17 years of experience in the pharmaceutical industry, most recently as the General Manager for Alcon Canada (A Novartis Company). Prior to joining Alcon, Ms. Symmes held roles of increasing responsibility within Novartis Canada including, Vice President Sales, and Vice President Specialty Medicines. Ms. Symmes holds an MBA from Charles Sturt University (Australia), an Honours BSc. in Kinesiology (Western University), and a post-graduate Management Diploma in Human Resources (Humber College).

Dr. Nathan Bryson , , , Vice President, Scientific Affairs

Dr. Bryson joined Acerus from Cynapsus Therapeutics where he served as Chief Scientific Officer. He brings more than 20 years of experience in pharmaceutical development, having held scientific and executive management level positions at several pharmaceutical companies including Flamel Technologies SA, Bionisis SA, and Matregen Corporation. Dr. Bryson holds a BSc in Chemistry from Auburn University and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology (“MIT”). He performed post-doctoral research under two well-esteemed chemists, the late Dr. J. Osborn at the University Louis Pasteur (Strasbourg, France) and Dr. D. Seyferth at MIT.

Philippe Savard , , , Vice President, Legal Affairs and Corporate Secretary

Mr. Savard serves as Vice President, Legal Affairs and Corporate Secretary with responsibility for protecting the legal interests of Acerus and managing its legal affairs. Prior to joining Acerus, Mr. Savard was Director & Counsel at DRI Capital Inc., a firm which manages private equity funds that purchase royalties owed on the sales of pharmaceutical products. Prior to his time at DRI Capital, Mr. Savard worked as an associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison LLP in Toronto, with a practice focused on transactional corporate securities, and as an associate at the law firm of Ropes & Gray LLP in New York, with a practice focused on corporate securities, mergers and acquisition and private equity. Mr. Savard holds a B. Sc. and a M. Sc. in Microbiology and Immunology from McGill University, a J.D. from the University of Toronto and a M.B.A. from the Rotman School of Management (University of Toronto).

Hélène Moore , , , Director, Business Development

Ms. Moore serves as Director, Business Development with responsibility for growing the Acerus portfolio of products via the identification, evaluation and pursuit of business opportunities in Canada and globally. Ms. Moore joined Acerus in 2015 and brings with her more than 15 years of sales and marketing experience with Bayer pharmaceuticals. Ms. Moore holds a B.Sc. Specialized in Biochemistry from Université de Montréal along with an executive M.B.A from Université du Québec à Montréal. She is also completing her Doctorate in Pharmaceutical Quantitative Marketing from the Goethe Frankfurt University in Germany.